1582P - Pain and bowel function evolution, in cancer patients treated with strong opioids at the first time that they report moderate-severe pain. C2 study

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Complications/Toxicities of Treatment
Supportive Measures
Presenter Iker Calderero
Authors I.L. Calderero1, L. Zugazabeitia Olabarria2, M.Á. Nuñez Viejo3, J.M. García Bueno4, E. Blanco Campanario5, J. Contreras Martínez6, M. López Mata7, J.L. Marti Ciriquian8, D. Isla Casado9, M. Provencio Pulla10
  • 1Radio-oncology Service, Hospital Virgen del Rocío, 41013 - Sevilla/ES
  • 2Oncology Service, Hospital Povisa, S.A, Vigo/ES
  • 3Oncology Service, Hospital Santa María Nai, Ourense/ES
  • 4Oncology Service, Hospital General de Albacete, Albacete/ES
  • 5Oncology Service, Hospital Infanta Cristina, Badajoz/ES
  • 6Radio-oncology Service, Complejo Hospitalario Regional Carlos Haya, Málaga/ES
  • 7Radio-oncology Service, Hospital Clínico Universitario Lozano Blesa, Zaragoza/ES
  • 8Oncology Service, Hospital General Universitario de Alicante, Alicante/ES
  • 9Oncology Service, Hospital Clínico Universitario Lozano Blesa, Zaragoza/ES
  • 10Oncology Service, Hospital Universitario Puerta de Hierro de Majadahonda, Madrid/ES


Introduction and objectives

Opioids remain the cornerstone of analgesic treatment for cancer patients, but gastrointestinal side effects have a great impact on their quality of life. The aim of this analysis was to evaluate the use of strong opioids in these patients, and if oxycodone/naloxone combination provides benefits in terms of analgesia, without compromising bowel function.

Material and methodology

Interim analysis of an observational multicentre study, in which patients reporting moderate-severe pain, at 1st time in the oncology services, were treated following investigator criteria. We present results of the patients treated with strong opioids during 1 month (N= 298).


Baseline characteristics: 65% male, mean ± SD age: 66 ± 13 years (27% ≥ 75 years old), ECOG 1: 54%; receiving chemotherapy 64% and radiotherapy 41%. Main location of the primary tumor: lung (28%), colon/rectum (12%), head and neck (11%). Metastatic cancer: 79%; 67% of patients reported pain secondary to metastases. Comparison between patients treated with oxycodone/naloxone (n= 217) with those treated with other strong opioids (n= 81) showed a good pain control in both groups (NRS0-10-2.7 and -2.2 points respectively, p = 0,08). It was confirmed a significant improvement of bowel function (<0.01) in patients treated with oxycodone/naloxone versus those treated with other strong opioides, which worsened their bowel function.


Clinical practice confirms significant improvements in pain relief in cancer patients reporting moderate pain at the first time in the oncology services, and treated with strong opioids. But patients treated with oxycodone/naloxone improve their bowel function, unlike those treated with other strong opioids.


All authors have declared no conflicts of interest.